Table 1 Baseline characteristics of patients by study and symptom duration group
Pooled data | Etanercept | Adalimumab | |||||||
|---|---|---|---|---|---|---|---|---|---|
<4 years | ≥4 years | P-value | <4 years | ≥4 years | P-value | <4 years | ≥4 years | P-value | |
n = 58 | n = 54 | n = 42 | n = 24 | n = 16 | n = 30 | ||||
Symptom duration mean (SD) | 2 (1.1) | 7.7 (5) | 2 (1.1) | 5.2 (0.9) | 1.9 (1) | 9.7 (5.9) | |||
Age, years, mean (SD) | 31.7 (8.1) | 37.8 (8.4) | 0.001 | 31.6 (8.2) | 37 (7.7) | 0.01 | 31.8 (8.1) | 38.5 (9.1) | 0.02 |
Male, n (%) | 30 (51.7) | 28 (51.9) | 0.99 | 25 (59.5) | 12 (50) | 0.45 | 5 (31.3) | 16 (53.3) | 0.15 |
HLA-B27-positive, n (%) | 45 (77.6) | 41 (75.9) | 0.84 | 33 (78.6) | 22 (91.7) | 0.17 | 12 (75) | 19 (63.3) | 0.42 |
Joints with arthritis, mean (SD) | 1.1 (3.3) | 1.7 (6.4) | 0.30 | 1.4 (3.9) | 1.9 (6) | 0.33 | 0.4 (0.7) | 1.6 (6.7) | 0.86 |
Joints with enthesitis, mean (SD) | 2.5 (3.6) | 3.5 (3.8) | 0.095 | 2.7 (4) | 3.7 (4.6) | 0.41 | 2 (2.7) | 3.3 (3.1) | 0.16 |
BASDAI, mean (SD) | 4.9 (1.9) | 6 (1.8) | 0.004 | 5 (1.7) | 5.5 (2) | 0.29 | 4.7 (2.4) | 6.3 (1.5) | 0.009 |
BASFI, mean (SD) | 3.8 (2.4) | 5 (2.1) | 0.007 | 3.9 (2.2) | 4.4 (2.3) | 0.34 | 3.6 (2.8) | 5.4 (1.9) | 0.01 |
BASMI mean (SD) | 1.5 (1.3) | 2.1 (1.8) | 0.057 | 1.7 (1.4) | 2.6 (2) | 0.04 | 1.1 (0.9) | 1.7 (1.6) | 0.16 |
ASDAS, mean (SD) | 3.1 (0.9) | 3.1 (0.8) | 0.95 | 3.2 (0.8) | 3 (1) | 0.49 | 2.9 (0.9) | 3.2 (0.6) | 0.22 |
CRP, mg/l, mean (SD) | 9 (9.3) | 6.9 (9.6) | 0.018 | 9.7 (10.4) | 8.8 (13.4) | 0.18 | 7.4 (6) | 5.4 (5.2) | 0.14 |
log CRP, mg/l, mean (SD) | 2 (0.7) | 1.7 (0.8) | 0.018 | 2.1 (0.8) | 1.8 (0.8) | 0.26 | 1.9 (0.7) | 1.5 (0.8) | 0.16 |
CRP-negative, n (%) | 26 (46.4) | 37 (71.2) | 0.009 | 18 (42.9) | 16 (66.7) | 0.04 | 8 (50) | 21 (70) | 0.18 |
MRI SIJ score, mean (SD) | 6.2 (6.1) | 4.1 (4.7) | 0.08 | 6.4 (6) | 5 (5.7) | 0.21 | 5.4 (7) | 3.2 (3.4) | 0.61 |